AxioMx Awarded SBIR Grant for Rapid scFv-to-IgG Conversion

Posted on Oct 13, 2015

Branford, Conn. – October 13, 2015. AxioMx announced that it has received a Phase I Small Business Innovative Research (SBIR) grant (1R43GM112204-01A1). This Phase I award, which will be administered by the National Institute of General Medical Sciences (NIGMS), will fund the development of a technique to rapidly convert single-chain variable fragments (scFvs) to full-length immunoglobulin…

READ MORE

AxioMx Launches AxioMx MembraneProSelect™ Service

Posted on Sep 22, 2015

September 22, 2015. AxioMx announced the launch of AxioMx MembraneProSelect™, a new service that enables the development of recombinant antibodies that recognize the native conformation of cell membrane protein extracellular domains (ECDs). The conformation of a cell membrane protein is heavily influenced by integration within membrane lipid bilayers. This presents a challenge during antibody development…

READ MORE

AxioMx Receives SBIR Grant for DNA-Protein Complex Antigen Development

Posted on Aug 31, 2015

August 31, 2015. AxioMx Inc., a leader in the development of high-quality recombinant antibodies, announced today that the National Institutes of Health (NIH) has awarded the company a Phase I Small Business Innovation Research (SBIR) grant (1R41DK104602-01), which will be administered by the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases. AxioMx will use…

READ MORE

AxioMx Receives SBIR Grant to Develop Multiplex Antigen Screening Technology

Posted on Mar 10, 2015

March 10, 2015. AxioMx announced today that the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant (1R43GM112385-01). This Phase I award, which will be administered by the National Institute of General Medical Sciences (NIGMS), will fund the development of multiplex antigen screening technology allowing the discovery of…

READ MORE

AxioMx Launches AxioMx Express – Custom Recombinant Antibodies in 5 Weeks

Posted on Jan 7, 2015

January 7, 2015. AxioMx announced the launch of AxioMx Express, a new service featuring rapid, five-week development of affordable custom recombinant antibodies. The AxioMx Express platform expands the range of custom recombinant antibody development options offered by AxioMx, an established leader in the field of antibody discovery. By streamlining and integrating its proprietary Rapid Liquid…

READ MORE

AxioMx Assists DTRA in the Development of Anti-Ebola Virus Antibodies

Posted on Dec 10, 2014

The global effort to combat the spread of Ebola has been joined by AxioMx which has formed a partnership with the Defense Threat Reduction Agency and the U.S. Army Edgewood Chemical Biological Center.

READ MORE

AxioMx Inc. Develops Novel Synthetic Antibody Library

Posted on Oct 6, 2014

AxioMx announced the successful completion of a highly diverse synthetic phage display antibody library. This will lead to antibody reagent development times of less than four weeks.

READ MORE

AxioMx Inc. Raises $2 Million in Second Round of Financing

Posted on Oct 8, 2013

BRANFORD, Conn. – October 8, 2013 – AxioMx Inc. announced today that it has completed its second financing round, raising $2 million in investment from Connecticut Innovations (CI), Elm Street Ventures, Vital Venture Capital and AxioMx company founders. “We are excited to add Vital Venture Capital to our group of investors, and we are inspired…

READ MORE

AxioMx, Inc. Announces Completion of Initial Financing

Posted on Dec 6, 2012

BRANFORD, CT – December 6, 2012 – AxioMx, Inc. announced today that it has completed its initial financing round with over $2 million in investment from Connecticut Innovations, Elm Street Ventures, and company founders. AxioMx provides a comprehensive custom recombinant antibody discovery and development service platform. Its service offerings include epitope mapping, antigen design, antibody…

READ MORE

AxioMx, Inc. Announces the Launch of Its Custom Recombinant Antibody Discovery and Development Services

Posted on Nov 7, 2012

BRANFORD, CT – November 7, 2012 – AxioMx, Inc. announced today the introduction of its custom recombinant antibody discovery and development services. These services include epitope mapping, antigen design, antibody screening and affinity maturation, antibody optimization, and antibody production. Using its proprietary phage display libraries and  “rapid liquid” approach to screening and affinity maturation, AxioMx…

READ MORE